Gemigliptin
ALIMENTARY TRACT AND METABOLISM
Also known as: LC15-0444, zemiglo
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Gemigliptin is a drug catalogued in DrugCentral. It was first approved by the Korean Food and Drug Administration (KFDA) in 2012. DrugCentral lists 2 molecular targets, including DPP4 and DPP9. Recorded indications include Diabetes mellitus type 2.
- Molecular targets: DPP4 and DPP9 (2 listed in DrugCentral).
- Indications: Diabetes mellitus type 2.
- ATC code: A10BD18 (Combinations of oral blood glucose lowering drugs).
- Molecular formula: C18H19F8N5O2; molecular weight 489.37 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Diabetes mellitus type 2
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Dipeptidyl peptidase 4 | DPP4 | inhibitor | IC50 7.80 |
| Dipeptidyl peptidase 9 | DPP9 | unknown | IC50 4.33 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2012-06-27 | Korean Food and Drug Administration (KFDA) | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A10BD18 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs |
A10BD30 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs |
A10BH06 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors |
A10BH52 | ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Gemigliptin is on its molecule page.
| Molecular formula | C18H19F8N5O2 |
|---|---|
| Molecular weight | 489.37 g/mol |
| CAS number | 911637-19-9 |
| InChIKey | ZWPRRQZNBDYKLH-VIFPVBQESA-N |
| PubChem CID | 11953153 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Gemigliptin used for?
DrugCentral lists the following indications for Gemigliptin: Diabetes mellitus type 2.
How does Gemigliptin work?
Its molecular targets in DrugCentral include DPP4 (inhibitor) and DPP9.
When was Gemigliptin first approved?
Gemigliptin was first approved by the Korean Food and Drug Administration (KFDA) in 2012.
What is the chemical formula of Gemigliptin?
Gemigliptin has the molecular formula C18H19F8N5O2 and a molecular weight of 489.37 g/mol.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4833 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3707235 — compound record and bioactivity
- PubChem CID 11953153 — chemical identifiers
- DrugBank DB12412 — drug record
- FDA UNII 5DHU18M5D6 — substance identity
- UniProt P27487 (DPP4) — target protein
- UniProt Q86TI2 (DPP9) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.